Carpenter Technology Corporation manufactures, manufactures and distributes specialty metals worldwide. The company is headquartered in Philadelphia, Pennsylvania.
| Revenue (TTM) | $3.03B |
| Gross Profit (TTM) | $900.60M |
| EBITDA | $765.90M |
| Operating Margin | 22.80% |
| Return on Equity | 24.90% |
| Return on Assets | 11.30% |
| Revenue/Share (TTM) | $60.42 |
| Book Value | $41.61 |
| Price-to-Book | 14.35 |
| Price-to-Sales (TTM) | 9.64 |
| EV/Revenue | 9.93 |
| EV/EBITDA | 38.30 |
| Quarterly Earnings Growth (YoY) | 47.30% |
| Quarterly Revenue Growth (YoY) | 11.60% |
| Shares Outstanding | $49.69M |
| Float | $48.43M |
| % Insiders | 2.37% |
| % Institutions | 97.86% |
Volatility is currently expanding
Carpenter Technology lifts its FY26 operating income outlook after a record third quarter, driven by aerospace and defense demand, pricing, and volume gains.
Carpenter (CRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Carpenter (CRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PHILADELPHIA, July 01, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, July 30, 2026 at 10:00 a.m. ET to discuss the results of operations for the fourth quarter of fiscal year 2026, ended June 30, 2026.
Carpenter (CRS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent Office has agreed to grant a patent covering POLB 001, Poolbeg's experimental treatment for preventing cytokine release syndrome (CRS), a dangerous immune reaction triggered by some cancer immunotherapies.
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Adstra Nonprofit today announced a strategic partnership with Catholic Relief Services (CRS), one of the world's leading humanitarian organizations.
